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1INTRODUCTION
Diabetes mellitus (DM) is a heterogenous group of metabolic
disorders recognized from ancient era which is characterized by chronic
hyperglycemia. The prevalence of diabetes especially type 2 DM is rapidly
increasing worldwide over the past two decades. In 2010, there were 285
million individuals worldwide with type 2 diabetes1. India had 41 million
diabetics in 2006, according to the International Diabetic Federation (IDF)
and it is expected to increase to 70 million by the year 20252. Diabetes was
responsible for almost four million deaths in 2010 (6.8% of deaths) and is
the fifth leading cause of mortality worldwide3. Cardiovascular
complications especially coronary heart disease are the most common
cause of morbidity and mortality in diabetics4.
Diabetes is an independent risk factor for cardiovascular disease4
and is designated as a “CHD risk equivalent” by the American Heart
Association5. The relative risk of cardiovascular disease is two to four fold
higher in people with diabetes6.The probability for a diabetic person to get
a first myocardial infarction is equal to that of a non diabetic person
getting it for the second time.7. The increased prevalence of CVD in
diabetes has been attributed in large part to the acceleration of coronary
atherosclerosis, which occurs at an earlier age and advances more rapidly
to clinical cardiovascular events in individuals with diabetes, with
2contribution from conventional risk factors for cardiovascular disease such
as hypertension, dyslipidemia and smoking8. A graded relationship also
exists between glycemic control (estimated by HbA1C level) and
cardiovascular risk 9.
Diabetes is now considered to be a proinflammatory10 and
procoagulant11 state and low grade chronic inflammation
(‘microinflammation’)10 is a key factor in the genesis and rupture of
atheromatous plaque. Hyperglycemia, oxidative stress, inflammation and
dysregulation of hemostasis contribute to the increased risk of diabetic
vasculopathies. Hence, the diabetes state per se confers an increased
propensity to accelerated atherogenesis, which is compounded by other
conventional cardiovascular risk factors12.
C reactive protein, measured as high sensitivity C reactive protein
(hsCRP) and fibrinogen are acute phase reactants synthesized in the liver
in response to proinflammatory cytokines. These markers of inflammation
are found to be elevated in individuals with type 2 DM and are emerging
as novel risk factors to assess cardiovascular risk. They also have positive
association with obesity, dyslipidemia, hypertension and poor glycemic
control13.
In our study, we analyzed the levels of hsCRP and fibrinogen in
individuals with type 2 DM and matched controls as a predictor of
cardiovascular risk and its relationship to glycemic control.
3AIMS AND OBJECTIVES
1. To assess and compare the high sensitivity C-reactive protein
(hsCRP) level in patients with type 2 diabetes without clinically
demonstrable vascular complications and that in matched controls.
2. To assess and compare the plasma fibrinogen level in patients with
type 2 diabetes without clinically demonstrable vascular
complications and that in matched controls.
3. To determine whether there is any correlation between high
sensitivity C-reactive protein (hsCRP) level and the degree of
glycemic control in patients with type 2 diabetes.
4. To determine whether there is any correlation between plasma
fibrinogen level and the degree of glycemic control in patients with
type 2 diabetes.
4REVIEW OF LITERATURE
For 2000 years, diabetes mellitus was recognized as a devastating
and deadly disease.
DEFINITION
Diabetes is a heterogenous group of metabolic disorders
characterized by hyperglycemia with disturbances of carbohydrate, fat and
protein metabolism resulting from defects in insulin secretion, insulin
action or both14.
THE HISTORY OF DIABETES
Earliest known record of diabetes was mentioned in 1552 BC, by
Egyptian physician Hesy-Ra of the 3rd Dynasty on the Ebers Papyrus15-17.
The term “diabetes” was coined by a Greek physician, Aretaeus of
Cappadocia in the 1st century AD from the Greek word for “siphon”18,19.
The word “mellitus” was added by Thomas Willis in the year 1675,
from the Latin word meaning honey, a reference to the sweet taste of
urine16,19,20. In 1776, Matthew Dobson confirmed that the sweet taste was
because of an excess kind of sugar in the urine and blood of people with
diabetes16.
5In 1889, the role of pancreas in the pathogenesis of diabetes was
first described by Joseph von Mering and Oskar Minkowsky of the
University of Strasbourg, France16,21.  In  1909,  Jean  De  Meyer  called  the
glucose lowering hormone produced by islet tissue as ‘insulin’16.
In 1921, the discovery and extraction of insulin at the University of
Toronto by a collaborate effort involving Sir Frederick G Banting, Charles
H Best,  James B Collip and J  J  R MacLeod revolutionized the history of
diabetes mellitus. In 1922, Leonard Thompson, aged 14, became the first
person to receive insulin injection to treat diabetes16,22. For this, Banting
and MacLeod received the Nobel Prize in Physiology or Medicine in the
year 1923. WHO, from the year 2007 onwards, celebrates World Diabetes
Day on November 14, on the birthday of Sir Frederick G Banting, in his
honour.
Eli Lilly began the commercial production of insulin (Isletin insulin)
in 1923. In 1936, Sir Harold Himsworth of the University College Hospital
in London proposed that diabetes falls into two types based on ‘insulin
insensitivity’. In 1940s link was made between diabetes and long term
complications of eye and kidney diseases. In 1942, sulphonyl urea, the first
oral hypoglycemic agent was discovered by M J Janbon16,23.
6In 1976, the glycosylated hemoglobin (A1C) test to monitor
glycemic control was introduced24,25. In 1978, first recombinant DNA
insulin was produced16,24. In 1983, first biosynthetic insulin was
introduced. “Reflolux”, later known as “ Accu-Chek” which allows blood
glucose self monitoring was introduced in the same year. In 2001, FDA
approved Glucowatch Biographer, the first noninvasive glucose monitor
for adults. Later Oral-Lyn, an oral spray formulation of human insulin
(2005) and Inhaled insulin (Exubera) (2006)26 was introduced.
EPIDEMIOLOGY OF DIABETES
WORLDWIDE
There is a dramatic increase in the prevalence of diabetes mellitus
especially type 2 DM, worldwide over the past two decades. It has
increased from 30 million cases in 1985 to 285 million in 2010 and is
projected to increase to the level of 438 million by the year 2030,
according to the International Diabetic Federation1. The greatest number of
individuals with diabetes will be aged 45-64 years in 2030, according to
worldwide estimates. The increase in the prevalence of type 2 DM
parallels the increase in obesity27 (hence the term “diabesity” by Ziv and
Shafrir28) and reduced activity levels as countries become more
industrialized, and with the aging of the population.
7 In 2010, the prevalence of diabetes ranged from 11.6 to 30.9%. 80%
of the people with diabetes live in low and middle income countries. The
ten countries with the highest prevalence in 2010 are Naurua, United Arab
Emirates, Saudi Arabia, Mauritius, Bahrain, Reunion, Kuwait, Oman,
Tona, Malaysia - in descending prevalence. There is variability in the
prevalence between countries and between ethnic groups within a country
owing to genetic, behavioural and environmental factors.
In the United States, diabetes was listed as the seventh leading cause
of death in 2007; a recent estimate suggested that diabetes was responsible
for almost four million deaths in 2010 (6.8% of deaths) and is the fifth
leading cause of mortality worldwide3, with cardiovascular complications
of diabetes being the major cause of mortality.
INDIAN SCENARIO
India had 41 million diabetics in 2006, according to the International
Diabetic Federation (IDF) and it is expected to increase to 70 million by
the year 20252. According to the World Health Organization (WHO)
estimates, India had 32 million diabetic subjects in 2000, which is
projected to increase to 80 million in 203029. The ‘Asian Indian phenotype’
with greater degree of central obesity30 as evidenced by greater waist
circumference and waist hip ratios, greater visceral adiposity31 (‘thin fat
8Indian babies’)32 and insulin resistance33 contributes to increasing
prevalence of type 2 diabetes in Asian Indians. Onset at a younger age is
also noted in this group. The disease has also encroached upon the middle
income and poorer sections of the Indian society and is no longer a disease
of the affluent alone34.The prevalence of coronary artery disease as a
complication of diabetes was 21.4% as compared to 9.1% in subjects with
normal glucose tolerance35. Also atherosclerosis, as assessed by carotid
intimal thickness was higher in type 2 diabetics36.The overall mortality rate
was three fold higher(18.9 vs 5.3 per 1000 person-years) among diabetics
as evidenced by Chennai Urban Population Study (CUPS) by Mohan V et
al. Coronary artery disease appears to be the leading cause of death in
majority of the studies37-39.
CLASSIFICATION OF DIABETES
Diabetes mellitus is classified into type 1 and type 2 based on the
pathogenic process leading to hyperglycemia. Complete or near-total
insulin deficiency due to destruction of pancreatic beta cells results in type
1 DM. The much more prevalent type 2 DM is characterized by variable
degrees of insulin resistance, insulin secretion and increased glucose
production. Both are preceded by a phase of abnormal glucose
homeostasis5.
9Etiologic classification of diabetes mellitus5
I.  Type 1 diabetes (?-cell destruction, usually leading to absolute
insulin deficiency)
              A. Immune mediated
              B. Idiopathic
II.  Type 2 diabetes (may range from predominantly insulin resistance
with relative insulin deficiency to a predominantly insulin secretory
defect with insulin resistance)
III.  Other specific types
A.  Genetic defects of beta cell function characterized by mutations in
Hepatocyte nuclear transcription factor (HNF)4?(MODY1); Glucokinase
(MODY2); HNF- 1?(MODY3); Insulin promoter factor-1
(IPF-1;MODY4); HNF-1? (MODY5); Neuro D1(MODY6);Mitochondrial
DNA; Subunits of ATP-sensitive potassium channel; Proinsulin or insulin
B. Genetic defects in insulin action
Type A insulin resistance; Leprechaunism; Rabson-Mendenhall
syndrome;   Lipodystrophy syndromes
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C.  Diseases of the exocrine pancreas- pancreatitis, pancreatectomy,
neoplasia, cysic fibrosis, hemochromatosis, fibrocalculous pancreatopathy,
mutations in   carboxylester lipase
D.  Endocrinopathies – acromegaly, Cushing’s syndrome,
pheochromocytoma, glucagonoma, hyperthyroidism, somatostatinoma,
aldosteronoma
E.  Drug-or chemical-induced – glucocorticoids, vacor (a rodenticide),
pentamidine, nicotinic acid, diazoxide, ?-adrenergic agonists, thiazides,
hydantoins, asparaginase, ?-interferon, protease inhibitors,
antipsychotics(atypical and others), epinephrine
F.  Infections – congenital rubella, cytomegalovirus, coxsackievirus
G.  Uncommon forms of immune- mediated diabetes- ‘stiff-person’
syndrome, anti-insulin receptor antibodies
H.  Other genetic syndromes sometimes associated with diabetes –
Wolfram’s syndrome, Down’s syndrome, Klinefelter’s syndrome, Turner’s
syndrome, Friedreich’s ataxia, Huntington’s chorea, Lawrence-moon-Biedl
syndrome, myotonic dystrophy, porphyria, Prader-Willi syndrome
IV.  Gestational diabetes mellitus (GDM)
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DIAGNOSIS OF DIABETES MELLITUS
The three categories of glucose intolerance include normal
glucose homeostasis, diabetes mellitus, and impaired glucose homeostasis.
1. Normal glucose tolerance – a fasting plasma glucose (FPG) <
100mg/dL (5.6mmol/L), a plasma glucose < 140 mg/dL (11.1
mmol/L) following an oral glucose challenge and an A1C <5.6%.
2. Diabetes mellitus
Criteria for the diagnosis of diabetes mellitus – American Diabetes
Association (ADA) 201140
A1C ? 6.5%. The test should be performed in a laboratory using a
method that is NSPG certified and standardized to the DCCT assay.*
Or
FPG ? 126mg/dL (7.0mmol/L). Fasting is defined as no caloric intake
for atleast 8 h.*
Or
2-h plasma glucose ?200mg/dL (11.1mmol/L) during an OGTT. The
test should be performed as described by the World Health Organization,
using a glucose load containing the equivalent of 75g anhydrous glucose
dissolved in water*
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Or
In a patient with classic symptoms of hyperglycemia or hyperglycemic
crisis, a random plasma glucose ? 200mg/dL (11.1mmol/L). Random is
defined as without regard to time since the last meal.
*In the absence of unequivocal hyperglycemia and acute metabolic
decompensation, result should be confirmed by repeat testing on a
different day.
3. Abnormal glucose homeostasis
Categories of increased risk for diabetes (prediabetes)*40
FPG 100-125mg/dL (5.6-6.9mmol/L) - Impaired Fasting Glucose (IFG)
Or
2-h plasma glucose in the 75-g OGTT 140 - 199 mg/dL (7.8 - 11.0
mmol/L)-Impaired Glucose Tolerance (IGT)
Or
A1C 5.7-6.4%
*For all three tests, risk is continuous, extending below the lower limit of
the range and becoming disproportionately greater at the higher ends of the
range.
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COMPLICATIONS OF DIABETES MELLITUS5
I. ACUTE
A. Diabetic ketoacidosis (DKA)
B. Hyperglycemic hyperosmolar state (HHS)
    II.  CHRONIC
          A. VASCULAR
              1. MICROVASCULAR
                  (A) Eye disease – Retinopathy (nonproliferative/proliferative)
                                             - Macular edema
                  (B) Neuropathy – Sensory and motor (mono- and
polyneuropathy)
                                             - Autonomic
                  (C) Nephropathy
               2. MACROVASCULAR
                  (A) Coronary heart disease
                  (B) Peripheral arterial disease
                  (C) Cerebrovascular disease
          B. Other
         1. Gastrointestinal (gastroparesis, diarrhoea)
         2. Genitourinary (sexual dysfunction/uropathy)
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         3. Infectious
         4. Hearing loss
         5. Cataracts
         6. Glaucoma
         7. Dermatologic
         8. Peridontal disease
MECHANISMS OF CHRONIC COMPLICATIONS OF DM
The majority of morbidity and mortality associated with diabetes
are due to its chronic complications in multiple organ systems as
mentioned above. The duration and degree of hyperglycemia determines
the risk of chronic complications. They usually appear in the second
decade of hyperglycemia.  But owing to the long asymptomatic period of
hyperglycemia in many individuals, they may present with complications
at the time of diagnosis. Genetic susceptibility also plays a role5.
The Diabetes Control and Complications Trial (DCCT)41 and the
United Kingdom  Prospective Diabetes Study (UKPDS)42 have established
the causative role for chronic hyperglycemia in the pathogenesis of
microvascular complications in both type1 and type2 diabetes mellitus,
whereas for macro- vascular complications it is less conclusive. They also
established that amelioration of hyperglycemia can modify this risk. In
15
individuals with type 2 DM, two to four times higher coronary heart
disease events and mortality are noted, which correlates well with fasting
and postprandial plasma glucose levels and A1C. Dyslipidemia and
hypertension also contributes to the development of macrovascular disease
in diabetics.
The vascular endothelial cells are unable to downregulate
glucose uptake under hyperglycemic conditions, due to free passage of
glucose through the endothelial cell membrane via the insulin-dependent
glucose transporter GLUT-1 and hence they are more prone for developing
intracellular hyperglycemia43. Four major biochemical pathways have been
proposed to explain the association between chronic hyperglycemia and
vascular damage.
A unifying hypothesis has been formulated whereby these four
pathways can be linked by a single hyperglycemia - driven process: the
mitochondrial overproduction of reactive oxygen species44.
1.            Formation of advanced glycosylation end products (AGEs)
 The process of formation of AGEs by irreversible nonenzymatic
glycosylation of intra- and extracellular proteins is markedly accelerated
by chronic hyperglycemia45. AGEs crosslink proteins (collagen,
extracellular matrix proteins), alter extracellular matrix structure and
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composition, promote glomerular dysfunction, reduce nitric oxide
synthesis, induce endothelial dysfunction and accelerate atherosclerosis.
2.  Increased flux through the polyol pathway
In an individual with chronic hyperglycemia, an increase in glucose
metabolism (upto 30% of glucose) via the sorbitol pathway occurs46.The
consumption of NADPH in the reduction of glucose to sorbitol by aldose
reductase and subsequent oxidative stress is the most likely mechanism of
damage47,48. Increased sorbitol concentration alters redox potential,
increases cellular osmolality, generates reactive oxygen species and lead to
cellular dysfunction.
3.  Activation of protein kinase C(PKC)
Intracellular hyperglycemia has been shown to stimulate de novo
synthesis of diacyl glycerol(DAG) .This increase in the DAG content in
turn activates protein kinase C, principally ? and ? isoforms49. Activated
PKC leads to endothelial dysfunction (suppression of nitric oxide
production and stimulation of endothelin-1 vasoconstrictor activity)50,
increased vascular permeability (via induction of vascular endothelial
growth factor, VEGF)51, accumulation of matrix proteins and mesangial
expansion through induction of transforming growth factor ?(TGF-?), type
IV collagen, and fibronectin52,53,and decreased fibrinolysis (via increased
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plasminogen activator inhibitor-1,        PAI-1)54. Finally, it also stimulate
NADPH oxidases, generating reactive oxygen species (ROS), leading to
increased oxidative stress.
4.  Increased flux through hexosamine pathway
The hexosamine pathway may alter cellular function by O-linked
glycosylation of proteins such as endothelial nitric oxide via UDP-N-acetyl
glucosamine or by changes in gene expression of transforming growth
factor ? (TGF-?) or plasminogen activator inhibitor-1(PAI-1)55-57.
CARDIOVASCULAR COMPLICATIONS IN DIABETES MELLITUS
There is an increased risk  of cardiovascular disease in both types of
diabetes mellitus. These account for the major mortality and morbidity in
type 2 diabetics58. It is shown that the relative risk of cardiovascular
disease is two to four fold higher in people with diabetes than in those
without diabetes59. A marked increase in PAD, CHF, CAD, MI and sudden
death (one- to five fold increase in risk) in DM was demonstrated in The
Framingham Heart Study5.     Uusitupa  et  al.  demonstrated  significantly
higher age standardized prevalence of acute MI among newly diagnosed
type 2 DM men (17%) and women (18%) as compared to non diabetics
(10% and 4%respectively). Also, during the ten year follow up, the
incidence of first MI was significantly higher among diabetic compared
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with nondiabetic persons (7% vs.19% for men; 12% vs.2% for women) and
also cardiovascular mortality60. The United Kingdom Prospective Diabetes
Study (UKPDS), followed up patients with newly diagnosed type 2
diabetes over a 10-year period, and showed that 8.4% of type 2 diabetic
patients  died of  either  fatal  MI or  sudden death42.  Excess mortality,  CVD
mortality in particular, extends beyond the limits of diabetes to impaired
glucose tolerance (IGT) as evidenced by studies in the United Kingdom, in
Whitehall61, London and in Bedford62.  Uusitupa  et  al.  also  showed that  a
considerable number of type2 DM patients had already suffered an MI
before the time of diagnosis of their diabetes63.
Diabetes confers an independent increased risk  for cardiovascular
complications. This is more so in the women ,in whom the diabetic status
confers an increased risk ,equal to that of risk that is attributed to the
overall male population 64,65. The American Heart Association has
designated DM as a “CHD risk equivalent”5. In a population based study
conducted by Haffner SM et  al,  the 7-year incidence of  first  MI or  death
for patients with diabetes was 20% vs.3.5% for non diabetic patients.
History of MI increased the rate of recurrent MI or cardiovascular death
for both groups (18.8% in non diabetics and 45% in those with diabetes).
Thus, the chance for a diabetic to get a first myocardial infarction is as
high as that of a second infarction in a non diabetic person66.
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Diabetics have greater acute as well as subsequent mortality
following an MI than nondiabetics67 and have increased risk of
reinfarction, congestive heart failure and death68.  According  to  the
FINMONICA study69, the largest population based study of the impact of
diabetes on mortality after the first MI,  1-year case-fatality rate for first
MI (including prehospitalization mortality) was 45% in diabetic men and
39% in diabetic women as compared to 38% and 25% in non diabetics
respectively. In short, in diabetics, CHD appears earlier in life, affects
women almost as often as men, involve multiple vessels, and is more often
fatal70.
In short cardiovascular complications of diabetes include
I. Atherosclerosis
Potential atherogenic mechanisms include
(a) Lipid and lipoprotein aberrations
(b) Procoagulant state
(c) Hyperinsulinemia and insulin-resistance syndrome
(d) Glycation of proteins (AGEs)
(e) Inflammation
(f) Oxidative stress
(g) Microalbuminuria
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     II. Syndrome X
     III. Congestive heart failure
     IV. Autonomic neuropathy
V. Preoperative evaluation and post operative risks
Cardiovascular Risk factors associated with diabetes and insulin
resistance71
A. Metabolic factors
1. Hyperglycemia
2. Insulin resistance
3. Hyperinsulinemia
4. Hypertriglyceridemia
5. Reduced HDL cholesterol
6. Small dense LDL
7. Hyperhomocysteinemia
B. Coagulation and inflammatory factors
1. Increased plasminogen activator inhibitor-1(PAI-1)
2. Increased platelet activation
3. Increased fibrinogen
4. Increased P-selectin, VCAM-1(vascular cell adhesion
molecule-1), and ICAM-1(intracellular adhesion molecule-1)
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5. Increased tissue factor and factor VII
6. Decreased nitric oxide bioavailabilty
7. Increased C-reactive protein
        C. Vascular related factors
              1. Hypertension
              2. Impaired endothelium-dependent vasorelaxation
              3. Increased arterial calcification
              4. Decreased arterial compliance
The increase in cardiovascular mortality and morbidity rates in
diabetes is due to the synergism of hyperglycemia with other
cardiovascular risk factors (dyslipidemia, hypertension, obesity, reduced
physical activity, cigarette smoking, microalbuminuria, macroalbuminuria,
elevated serum creatinine, abnormal platelet function, insulin resistance
and hyperinsulinemia, elevated levels of plasminogen activator inhibitor
(PAI-1) and fibrinogen, endothelial and vascular smooth muscle
dysfunction). Large benefits are seen when multiple risk factors are
addressed globally72,73.
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TRADITIONAL CARDIOVASCULAR RISK FACTORS IN DIABETES
The traditional risk factors such as hypertension, dyslipidemia,
obesity, reduced physical activity and cigarette smoking play an important
role in the development of coronary heart disease in diabetic patients65.
Hypertension:
Hypertension is a major CVD risk factor that often coexists with
diabetes and insulin resistance74. The prevalence of hypertension in
diabetic appears to be approximately twice as high as in non diabetics in
the same population75. According to the joint data from Finnish and Dutch
cohorts of the Seven Countries Study, glucose intolerance was proposed to
be a stronger correlate of hypertension than is hyperinsulinemia76.
Autooxidation of glucose77, leading to the generation of oxygen-derived
free radicals which in turn inactivate endothelium-derived releasing
factors78 and selectively attenuate endothelium dependent relaxation79
contributes to elevated blood pressure in diabetics. The postprandial
hypertriglyceridemia also have independent and cumulative deleterious
effect on endothelial function through oxidative stress80.
Epidemiologic analyses have revealed that in individuals with
diabetes, blood pressure values >115/75 mmHg are associated with
increased cardiovascular event rates and mortality65,81,82. A doubling in the
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risk  of  CVD  was  shown  for  each  incremental  increase  in  BP  of
20/10mmHg above 115/75 mmHg and for every 10mmHg reduction in
systolic BP, and the risk of any diabetes-related complication decreased by
12%83.The  benefit  of  intensive  blood  pressure  control  in  diabetics  with
regard to cardiovascular disease, stroke, retinopathy and nephropathy is
also shown by  various trials like The Appropriate Blood Pressure Control
in Diabetes and the Hypertension Optimal Treatment (HOT)84 .
According to these results,  the American Diabetes Association
along with AHA and ACC have set 130/80mmHg or lower as target BP in
patients with diabetes40,86.  The  treatment  of  hypertension  consists  of
lifestyle therapy and pharmacologic therapy40. Life style therapy includes
weight loss in overweight individuals, Dietary Approaches to Stop
Hypertension (DASH)-style dietary pattern including reducing sodium and
increasing potassium intake; moderation of alcohol intake; and increased
physical activity. Drug therapy is initiated with either ACE inhibitor or an
ARB (shown to reduce the incidence of various cardiovascular end points
in multiple studies)87-91, with diuretics as the next add on therapy, usually
requiring multiple drug therapy.
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Dyslipidemia
The most common pattern of dyslipidemia in type 2 diabetes is
decrease in HDL cholesterol level and an increase in the triglyceride. LDL
cholesterol levels are usually normal . The importance is that the LDL
particles in diabetics  are more atherogenic93 .  This  was  mentioned  as
diabetic dyslipidema by Erkelens.92As part of comprehensive diabetes
care, lipid abnormalities should be assessed and treated aggressively due to
the additive cardiovascular risk of hyperglycemia and
hypertriglyceridemia5.
Analyzing subgroup of individuals with diabetes in various trials of
primary prevention, statistically significant benefit with regard to CVD
was found in the Heart Protection Study (HPS)94,95 and  Anglo-
Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-
LLA)96 using statins. The Collaborative Atorvastatin Diabetes Study
(CARDS), conducted with 10 mg atorvastatin in individuals with type 2
diabetes, showed a decrease in risk by 37% for cardiovascular events, and
by 48% for stroke and 27% in total mortality97.
Among the secondary prevention trials with diabetes subgroup
analyses, statistically significant benefit with regard to cardiovascular
event was noted in the Heart Protection Study(HPS)94,95, the Scandinavian
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Simvastatin Survival study(4S)98, The Lescol Intervention Prevention
Study(LIPS)99,  the  Cholesterol  and  Recurrent  Events  (CARE)study100, all
using statins and with gembrozil in Veterans Administration High-Density
Lipoprotein Cholesterol Intervention Trial(VA-HIT)101 .
The current guidelines in the treatment of dyslipidemia in diabetics
are provided by the ADA40 and the AHA. The first priority is to lower the
LDL cholesterol followed by raising the HDL cholesterol and decreasing
the triglycerides. Initial therapy includes lifestyle modification (smoking
cessation, increased physical activity, weight loss, blood pressure control)
and dietary changes as advocated by the National Cholesterol Education
Program to increase monounsaturated fats, carbohydrates, omega-3 fatty
acids and viscous fibre and to reduce saturated fats and cholesterol.
Improvement in glycemic control will lower triglycerides and raise HDL.
The target lipid values in diabetic individuals (>40years) without
cardiovascular disease are LDL<100mg/dL (2.6mmol/L); HDL>40mg/dL
(1mmol/L) in men and >50mg/dL (1.3mmol/L) in women; and
triglycerides <150mg/dL (1.7mmol/L). The agents of choice for lowering
the LDL level are HMG-CoA reductase inhibitors. In patients >40 years ,
in those with CHD and in those without CHD, but who have CHD risk
factors, addition of a statin regardless of the LDL level is recommended.
Reducing LDL cholesterol levels to 70 mg/dL was associated with a
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reduction in cardiovascular events in studies like HPS94,95, CARDS97 and
Incremental Decrease in End Points through Aggressive Lipid Lowering
(IDEAL)102. In keeping with this, and the evidence in nondiabetic
individuals with CHD, the ADA recommends an LDL goal of < 70mg/dL
(1.8mmol/L) as an ‘option’ in patients with known CHD5.
Smoking
Smokers have an increased rate of CVD, premature death, and
increased rate of microvascular complications of diabetes and also may
have a role in the development of type 2 diabetes. According to the ADA
recommendations, all diabetic patients are advised not to smoke, and
smoking cessation counselling, assessment of level of nicotine dependence
and addition of pharmacological therapy in those motivated to quit should
become a part of routine diabetes care40.
Obesity
As many as 80% of individuals with type 2 diabetes are obese.
Obesity is associated with other cardiovascular risk factors such as poorer
glycemic control, higher blood pressures and atherogenic lipid
profiles106,107 (especially with abdominal obesity) and decreased levels of
vascular protective adipokine-adiponectin; hence the need for active
interventions to control weight gain. According to the Framingham study,
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obesity (waist-to-hip ratio being the best predictor) was an independent
risk factor for 26 year incidence of cardiovascular disease in men and
women (including coronary disease, stroke and congestive heart failure).
Weight loss is recommended for all overweight or obese individuals with
type 2 diabetes as it is known to reduce insulin resistance. A low-
carbohydrate, low-fat, calorie-restricted diet or Mediterranean diets may be
effective in the short term (upto 2 years). Medical Nutrition Therapy
(MNT) with a registered dietician is recommended.
Regular exercise also plays an important role in weight loss
programs and are most helpful in maintenance of weight loss. It also
improves blood glucose control and insulin sensitivity, reduce
cardiovascular risk factors and improve well-being103. ADA recommends
atleast 150min/week of moderate intensity aerobic physical activity (50-
70% of maximum heart rate) and resistance training three times per week
in the absence of contraindications (cardiovascular status should be taken
into consideration)40. A reduction in the A1C level by an average of 0.66%
was noted in type 2 diabetics with structured exercise interventions of
atleast 8 weeks duration, even with no significant change in BMI104,105.
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Role of glycemic control
The  Norfolk Cohort of the European Prospective Investigation of
Cancer and Nutrition(EPIC-Norfolk) demonstrated that HbA1C was
independently and continuously related to all-cause, cardiovascular and
ischemic heart disease mortality throughout the whole population
distribution. A 28% increase in the risk of death in men (p<0.002)
independent of age, blood pressure, serum cholesterol, body mass index
and cigarette smoking was noted with each 1% increase in HbA1C. An
association between glucose and cardiovascular disease also existed at
levels below those used to define diabetes108.  ADA  recommends  an
HbA1C <7% as the target for adequate glycemic control40.
NOVEL CARDIOVASCULAR RISK FACTORS
The novel risk factors, shown to predict increased cardiovascular
risk includes hsCRP and other markers of inflammation, lipoprotein(a),
homocysteine, and markers of fibrinolytic and hemostatic function, such as
fibrinogen, D-dimer, tissue plasminogen activator (t-PA), and plasminogen
activator inhibitor 1 (PAI-1) antigens.
ATHEROSCLEROSIS AND DIABETES
Diabetes is associated with accelerated atherosclerosis. It has been
established that hyperglycemia, oxidative stress, and inflammation play a
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key role in atherogenesis as evidenced in diabetic vasculopathies. Libby
and Ross have given evidence that all phases of atherosclerosis from the
initiation of the fatty streak to the culmination in acute coronary
syndromes (plaque rupture) involves inflammation109,110
(‘microinflammaion’). Diabetes is a pro-inflammatory state as evidenced
by increased high-sensitivity C-reactive protein, fibrinogen, plasminogen
activator inhibitor 1, pro-inflammatory cytokines, soluble cell adhesion
molecules and nuclear factor ?? activity.
C-REACTIVE PROTEIN
CRP, an acute-phase reactant, a simple downstream marker of
inflammation, has now emerged as a major cardiovascular risk factor. It is
a member of the pentraxin family and has a cyclic pentameric structure111.
It plays a major role in the human innate immune response. Its synthesis in
the    liver is triggered by various proinflammatory cytokines derived from
various sources including monocytes, macrophages and adipose tissue.
Studies have shown that cells in the human coronary artery particularly
atherosclerotic intima can also produce CRP.
 The oxidative stress and infectious agents such as Cytomegalovirus
trigger a proinflammatory response in the vessel wall leading to increased
secretion of interleukin-1?(IL-1?) and the proinflammatory cytokine
30
tumour necrosis factor ?(TNF-?) which inturn releases cytokine IL-6,
especially from the macrophages. IL-6, on binding to receptors in the liver
causes  secretion  of  CRP  and  Serum  Amyloid  A  protein  (SAA).  CRP
decreases endothelial nitric oxide production, increases release of adhesion
molecules and PAI-1, promotes increased oxidized LDL uptake, increases
release of ROS and proinflammatory cytokines112.
The Pickup’s group demonstrated that both IL-6 and high
sensitivity-CRP are elevated in diabetic patients113.  The  Tan’s  group  also
demonstrated higher CRP levels in type 2 diabetic patients than matched
non-diabetic controls114.  Ford  and  co-workers  in  the  NHANES  III
(National Health and Nutrition Examination Survey) noted that persons
with diabetes or with impaired fasting glucose have increased levels of
CRP compared with those who have normal fasting glucose115. High
dietary glycemic load can also raise plasma concentrations of CRP,
accounting for the increased level of CRP in type 2 DM116. The high CRP
concentrations also appear to predict type 2 DM as evidenced by the
Cardiovascular Health Study117,  the  Women’s  Health  Study118, the
MONICA Augsburg Cohort Study119 and  IRAS120, supporting a role for
chronic inflammation in the pathogenesis of diabetes.
Inflammation is also associated with many metabolic abnormalities
associated with diabetes, especially with insulin resistance. The individuals
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with type 2 diabetes with more than two features of the metabolic
syndrome had more inflammation as evidenced by increased serum CRP
and IL-6 levels113.  In the Insulin Resistance and Atherosclerosis Study
(IRAS), Festa and co-workers showed that hsCRP positively correlated
with BMI, waist circumference, total cholesterol, triglycerides, LDL
cholesterol, plasma glucose and fasting insulin. hsCRP was inversely
correlated with HDL cholesterol and insulin sensitivity index. The
strongest correlation of CRP was reported with BMI and insulin sensitivity
index and a linear increase in CRP levels was noted with increase in the
number of metabolic disorders120. Thus, hsCRP assessment also adds
prognostic information at all levels of the metabolic syndrome 121,122. So we
can conclude that even for individuals with the Adult Treatment Panel
(ATP-III) definition of metabolic syndrome, knowledge of hsCRP levels
can predict risk groups for future vascular events.
In various studies involving primary prevention it is demonstrated
that CRP, when measured with high sensitive assays (hsCRP) strongly and
independently predicts risk of coronary vascular disease (CVD) including
coronary artery disease, stroke, peripheral arterial disease and sudden
death across all age levels, in both sexes and in diverse populations.
Various studies have found the risk of hsCRP to be independent of and
additive to traditional risk factors123-126. The magnitude of effect of hsCRP
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is at least as large as that of hypertension and smoking, this underscores
the importance of inflammation in atherogenesis127. hsCRP indicates an
increased propensity for plaque disruption and/or thrombosis more than the
presence of subclinical disease. Studies have shown that hsCRP levels
correlate modestly with underlying atherosclerotic disease as measured by
carotid intimal medial thickness129 or  by  coronary  calcification.  hsCRP
levels also predict incident hypertension and add prognostic information
on vascular risk at all levels of blood pressure129,130. hsCRP levels have
been proved to have strong predictive value for poor short- and long-term
cardiovascular outcomes in allograft atherosclerosis132 and chronic renal
failure and dialysis131.
Most importantly, hsCRP adds prognostic information at all levels
of  LDL  cholesterol  and  at  all  levels  of  risk,  as  determined  by  the
Framingham Risk Score133. Some others have shown that hs-CRP is a
better predictor of subsequent risk than LDL cholesterol level itself 134,135.
Since hsCRP and cholesterol reflect different components of vascular risk,
the addition of hsCRP to lipid evaluation provides a greater opportunity to
improve global risk prediction. The absolute vascular risk is higher in
individuals with elevated hsCRP levels and low levels of LDL cholesterol
than in those with elevated levels of LDL cholesterol but low levels of
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hsCRP, but current guidelines consider only the latter group to be at high
risk.
The guidelines in 2003 issued by  the American Heart Association
and the Centres for Disease Control and Prevention regarding the use of
hsCRP in clinical practice136  interprets  hsCRP levels  less  than  1,  1  to  3,
and higher than 3 mg/L as lower, moderate, and higher relative vascular
risk, respectively, when considered along with traditional markers of risk.
Its greatest usefulness is likely to be for those at intermediate risk—that is,
individuals with anticipated 10-year event rates between 5 and 20 percent,
although hsCRP predicts risk across the entire population spectrum. The
global risk prediction models that included hsCRP reclassified
approximately 20 percent of those individuals otherwise considered to be
at intermediate risk.  In recent studies, it is shown that the impact of hsCRP
on risk prediction was at least as large as that of lipid screening 137. Recent
studies have demonstrated that the Reynolds Risk Score combining hsCRP
and information on family history of coronary heart disease (history of MI
in a parent before 60 years) with the Framingham risk factors more
accurately estimate cardiovascular risk in both men and women. Newer
guidelines by the Canadian Cardiovascular Society in 2009, after taking
into consideration the results of Justification for the Use of Statins in
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Prevention And Intervention Trial Evaluating Rosuvastatin (JUPITER)138
call for measurement of hsCRP in all patients with intermediate risk.
Screening for hsCRP is not to be considered as a replacement for
LDL  and  HDL  testing.  Rather  it  should  be  done  at  the  discretion  of  the
physician as part of global risk evaluation on an outpatient basis at the time
of cholesterol evaluation. hsCRP levels are stable over long periods, have
no circadian variation, and do not depend on prandial state. The
cardiovascular risk appears to be linear across the full range of hsCRP
levels126. hsCRP values  more than 8 mg/L may represent an acute-phase
response caused by an underlying inflammatory disease or intercurrent
infection; but consistently high values, as evidenced by repeat testing
approximately two to three weeks later, however, represent very high risk
of future cardiovascular disease .
Levels  of  hsCRP  greater  than  3  mg/L  also  has  prognostic  role  in
acute ischemia even without troponin level elevation139, and predicts poor
outcome in the setting of unstable angina, recurrent coronary events,
thrombotic complications after angioplasty,  and vascular complications
after bypass surgery in those with established coronary heart disease.
Hence individuals with elevated hsCRP levels are also more likely to
benefit from aggressive interventions compared with those with low
hsCRP levels.
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Statins lower hsCRP levels in a manner largely unrelated to the
magnitude of LDL cholesterol reduction141. Statin therapy prevents first
vascular events, not only in patients with elevated LDL cholesterol levels,
but also in those with elevated levels of hsCRP as demonstrated in
AFCAPS/TexCAPS trial 140. The concept of dual goals for statin therapy
which includes both CRP and LDL reduction has emerged with the results
of  the PROVE IT-TIMI 22 clinical trial conducted in patients with acute
coronary syndromes treated with statin therapy; the best long-term
outcomes were found in those who achieved reduction of hsCRP less than
2mg/L and LDL cholesterol less than 70 mg/dL142.
The recent JUPITER trial showed that statin use in healthy men
aged > 50 years and in healthy women aged > 60 years with an LDL of <
130 mg/dL and an hsCRP level of > 2 mg/L decreased the incidence of a
first major cardiovascular event (eg, MI, stroke, arterial revascularization
procedure, hospitalization with unstable angina, or death from
cardiovascular causes) by 44% (P< 0.001).  A 55% reduction was observed
for the end point of MI, whereas for stroke, a 48% reduction was observed.
For the prevention of one event, the estimated number needed to treat for 2
and 4 year was 95 and 31, respectively143, which makes this approach more
efficient than the treatment of either hyperlipidemia or hypertension in
similar primary prevention patients. In a recently published subanalysis of
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JUPITER, Ridker et al showed that the best cardiovascular outcomes
occurred in patients who attained an LDL-C of < 70 mg/dL and an hsCRP
level  of  <  1  mg/L  with  statins138. Treatment with fibrates, niacin,
thiazolodinediones may also lower hsCRP levels. The usefulness of aspirin
in preventing first vascular events appears to be highest for patients with
elevated hsCRP levels, even though aspirin has not shown to reduce
hsCRP levels. This suggests individuals with high hsCRP levels may
benefit from the use of aspirin for primary prevention.
Current strategies recommend aggressive primary prevention in
those individuals with LDL cholesterol >160 mg/dL and elevated hsCRP
levels. This may also motivate some patients to comply with life style
modifications and pharmacotherapy. In those with LDL cholesterol levels
between 130 and 160mg/dl, the finding of an elevated hsCRP level
indicates substantial risk and, again, should lead to better adherence to
preventive efforts and perhaps to earlier use of pharmacological
approaches to risk reduction. For individuals with LDL cholesterol levels
below 130 mg/dl, an elevated hsCRP value also confers elevated risk. Such
individuals should thus aggressively undergo lifestyle modification
(physical activity, weight loss, and smoking cessation programs) with
earlier pharmacotherapy. As noted earlier, in patients with acute coronary
syndromes, reaching an hsCRP level less than 2 mg/L appears to be as
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important for long-term outcomes as reaching an LDL cholesterol level
less than 70 mg/dl. The newer guidelines, such as those issued in 2009 in
Canada, now list an hs-CRP level of < 2 mg/L as a secondary target for
statin therapy.144
DYSREGULATION OF HEMOSTASIS IN DIABETES
Both diabetes and insulin resistance are prothrombotic states.
Disturbances of the hemostatic system favour the development of vascular
damage and thrombosis at the site of an acutely ruptured atherosclerotic
plaque. Changes in the hemostatic system seen in diabetes include
hyperactivity of platelets, high levels of fibrinogen, which promotes
platelet aggregation and induces rheological changes and the formation of
a rich fibrin clot, activation of endothelial cells and leucocytes,
hypercoagulabilty with increased formation of multipotent thrombin and
decreased fibrinolytic activity due to an increased plasma level of
Plasminogen activator inhibitor-1(PAI-1)
Hyperglycemia per se through the formation of AGEs release
proinflammatory cytokines which increases cell surface adhesion
molecules such as vWF, decrease production of nitric oxide, promotes
oxidative stress, forms glycated fibrin and glycated platelet glycoproteins
with altered function.
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FIBRINOGEN
Fibrinogen, like CRP, is an acute-phase reactant and increases
during inflammatory responses. Fibrinogen was among the first “novel”
cardiovascular risk factors to be evaluated. Also known as clotting factor I,
it is a soluble glycoprotein synthesized in the liver. The fibrinogen is an
asymmetrical molecule, which is highly elongated having an axial ratio of
20:1, the asymmetry and large size of which contributes to the viscosity of
blood145.
Plasma fibrinogen influences platelet aggregation and blood
viscosity, interacts with plasminogen binding and, in combination with
thrombin, mediates the final step in clot formation and the response to
vascular injury146. In addition, fibrinogen associates positively with age,
obesity, smoking, diabetes and glycemic control, and LDL cholesterol
level, and inversely with HDL cholesterol level, alcohol use, physical
activity, and exercise level.
Several studies have shown that fibrinogen levels are increased in
type 2 DM patients and they are closely related with the presence of
vascular complications147,148. Kannel B et al, in his study showed that there
was an increase in fibrinogen values throughout the range of blood sugar
levels149. Graziella Brino et al studied the association of serum fibrinogen
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level with glycemic control in 1525 patients and found that noninsulin
dependent diabetic patients had a high prevalence of hyperfibrinogenemia
and that fibrinogen level was independently associated with HbA1c
value150. Hyperfibrinogenemia in diabetes has been reported to be caused
by an increased synthesis of fibrinogen that is not compensated for by a
proportional increase in clearance of fibrinogen. These abnormalities have
been associated with insulin deficiency, suggesting that
hyperfibrinogenemia is an expression of poor glycemic control.
In review of risk factors for coronary artery disease Jarrett RJ has
mentioned that increased fibrinogen, lipoprotein abnormalities and
increased platelet adhesiveness contribute to the same151. Graziella Bruno
et al150, Kannel W B et al149, Lee AJ152 et al have  also found an association
between increased plasma fibrinogen level and increased cardiovascular
risk in diabetic patients. Also the Gothenburg, Northwick Park153, and
Framingham heart studies all found significant positive associations
between fibrinogen levels and future risk of cardiovascular events and that
there was an approximately linear logarithmic association between usual
fibrinogen level and the risk of coronary heart disease and stroke,
independent of hsCRP levels. In one analysis, the age- and gender-adjusted
hazard ratio per 1-g/L increase in fibrinogen was 2.4 for coronary heart
disease and 2.1 for stroke.154
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In more recent studies, hsCRP and fibrinogen levels appeared to be
additive in their ability to predict risk, although the absolute effect of
hsCRP appeared to be larger. Also there are studies to suggest that the
predictive usefulness of fibrinogen is highest in those with other
concomitant elevations of lipoprotein(a) or homocysteine.
It has been observed that fibrates and niacin lower fibrinogen levels
but statin therapy does not, an effect different than that observed for
hsCRP. The potential benefits of fibrinogen reduction has to be studied
further. The Bezafibrate Infarction Prevention Trial did not show
significant reduction in event rates with active therapy despite a significant
reduction in fibrinogen levels and despite evidence that within the study
population, baseline fibrinogen levels predicted vascular risk.155
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MATERIALS AND METHODS
SETTING
Department of Internal Medicine
Government Stanley Medical college and Hospital
Chennai – 600 001
INSTITUTIONAL ETHICS COMMITTEE APPROVAL
Obtained
STUDY DESIGN
To  assess  the  level  of  hsCRP  and  plasma  fibrinogen  level  as  a
predictor of cardiovascular risk in individuals with type 2 diabetes
mellitus, and its relationship to glycemic status, an observational case-
control study was chosen.
PERIOD OF STUDY
May 2011 to November 2011
SAMPLE SIZE
Cases : 50 ; Controls : 50
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INCLUSION CRITERIA
Diagnosis of Diabetes Mellitus according to criteria put forward by
American Diabetic Association (ADA) - Standards of Medical care in
Diabetes 2011.
Diabetic patients were classified as type 2 using the following parameters
    : age of onset – after 30 years.
    : those who did not require insulin therapy initially.
EXCLUSION CRITERIA
1.  Diabetic patients with clinical evidence of neuropathy,
nephropathy, retinopathy
 2.  Diabetic ketoacidosis and nonketotic hyperglycemic coma
 3.   Coronary artery disease
 4.   Peripheral vascular disease
 5.   Cerebrovascular disease
 6.   Liver disease
 7.   Renal disease
 8.   Pregnant diabetics
 9.   Acute infections
10.  Smokers and alcoholics
11.  Patients above the age of 50 yrs (to exclude asymptomatic
ischemic heart   disease)
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STUDY PROTOCOL
A  total  of  100  patients  who  attended  our  outpatient  clinic  at  the
Government Stanley Medical College and Hospital were enrolled into the
study. Of these fifty patients who met the criteria were selected as cases
and 50 patients who came for Master health checkup were selected as
controls.
The patients with the following criteria (according to the ADA-
Standards of Medical Care in Diabetes 2011) were defined as having
diabetes mellitus:
A1C ? 6.5%. The test should be performed in a laboratory using a
method that is NSPG certified and standardized to the DCCT assay.*
Or
FPG ? 126mg/dL(7.0mmol/L). Fasting is defined as no caloric
intake for atleast 8 h.*
Or
2-h plasma glucose ?200mg/dL(11.1mmol/L) during an OGTT. The
test should be performed as described by the World Health Organization,
using a glucose load containing the equivalent of 75g anhydrous glucose
dissolved in water*
Or
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In a patient with classic symptoms of hyperglycemia or
hyperglycemic crisis, a random plasma glucose ? 200mg/dL(11.1mmol/L).
Random is defined as without regard to time since the last meal.
*In the absence of unequivocal hyperglycemia and acute metabolic
decompensation, result should be confirmed by repeat testing on a
different day.
Diabetic patients were classified as type 2 using the following
parameters:
1. Age of onset-after 30 years.
2. Those who did not require insulin therapy initially.
For each enrolled subject, an informed written consent was
taken. A detailed history was taken from each patient including details
regarding the diagnosis, duration of diabetes, type of treatment, followup
and other comorbidities. The duration of diabetes was not given greater
emphasis as asymptomatic hyperglycemia persists in many much before
the detection of their diabetic status.A complete physical examination of
each patient was done which included search for peripheral vascular
disease, cerebrovascular disease, cardiovascular disease, neuropathy,
retinopathy and nephropathy.
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Blood pressure was measured in the right arm in the sitting position
with the arm supported using a mercury sphygmomanometer to the nearest
2mmHg, and repeated after 5 minutes rest if the first reading was high.
Height was measured to the nearest mm with a stadiometer. Weight was
measured and Body mass index was calculated using the following
formula –
 BMI = Weight in Kgs / (Height in Ms).2
Basic blood investigations including hemoglobin, total and
differential counts, platelet counts, blood urea, serum creatinine, and liver
function tests were done. Urine albumin, sugar, microscopy and ketone
body estimation were done. A standard 12-lead resting electrocardiography
and X-ray screening of chest and echocardiography was done. A fasting
lipid profile including serum total cholesterol, triglycerides, high density
lipoprotein(HDL), low density lipoprotein(LDL) was obtained. Fasting and
2-hour postprandial blood samples were obtained. Glycosylated
hemoglobin(HbA1C) was done by Biorad HPLC assay. Normal value was
taken as 4-6%. Patients with HbA1C ? 8% were categorized as those
having poor control.
Plasma fibrinogen was estimated by automated optical light
scattering method. Normal range is 180-350mgs/dL. High sensitive C-
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reactive protein (hsCRP) was measured by immunoturbidometry and
values more than 3.0 mg/L accounted for high cardiac risk. Values more
than 10mg/L is suggestive of other inflammatory diseases or infection. The
study group was compared with an age and sex matched control group of
non diabetics .The results were recorded in a standard proforma.
STATISTICAL ANALYSIS
Statistical analysis was done in all the 100 subjects (50 cases and 50
controls) after categorizing the variable. Age, body mass index(BMI),
systolic blood pressure, diastolic blood pressure, serum total cholesterol,
triglycerides, LDL cholesterol, HDL cholesterol, fasting blood sugar, 2-
hour postprandial blood sugar, HbA1C , plasma fibrinogen, hsCRP of all
subjects were the parameters analysed. Statistical analysis was carried out
with  SPSS  software.  Pearson  correlation  coefficient  and  students  t  test
were done to find out correlations and significant differences between the
two groups. Statistical significance was taken when the p value as <0.05.
OBSERVATIONS AND RESULTS
In this study there were 50 patients in the study group which
included 27 males and 23 females. The control group also had 50 subjects,
ie, 22 males and 28 females.
AGE
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In the study group, age of the patients ranged from 32 to 49 years,
with a mean and standard deviation of 41.10 and 4.00 respectively. The
majority of the patients belonged to the age group 40-44 years (56%).
Among the controls, age ranged from 30 to 49 years. The mean and
standard deviation were 40.04 and 4.28 respectively. Majority were in the
age group 40-44 years (52%).
Table – 1 Distribution of cases and controls by age group
Age in
Years
Study group (n = 50) Control group (n =50)
Number Percentage Number Percentage
30-34      3 6.00 4 8.00
35-39      14 28.00 16 32.00
40-44      28 56.00 26 52.00
45-49      5 10.00 3 6.00
BODY MASS INDEX
The BMI of the study group ranged from 21.51 to 30.82kg/m2. The
mean and standard deviation were 25.10 and 1.67 respectively.
Among the controls, BMI varied from 21.64 to 27.06 kg/m2 with a
mean of 24.18 and a standard deviation of 1.43.
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Table 2- Distribution of subjects in study group according to Body
Mass Index
BMI(kg/m2) Number ( n = 50) Percentage
<18.5 0 0
18.5 – 24.9 28 56
25 – 29.9 21 42
30 -34.9 1 2
Table 3- Distribution of subjects in control group according to Body
Mass Index
BMI (kg/m2) Number ( n=50) Percentage
<18.5 0 0
18.5 – 24.9 37 74
25 – 29.9 13 26
30 – 34.9 0 0
HYPERTENSION
Among the 50 subjects in the study group, 32(64%) were found to
be hypertensive and the remaining 18(36%) were non hypertensives. Of
the 32 hypertensive, 15 were males and 17 were females.
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Among the 50 subjects in the control group, 8(16%) were
hypertensives and 42(84%) were non hypertensives. Of the 8
hypertensives, 4 were males and 4 were females.
Table 4 – Hypertension in the study group and control group
Study group (n=50) Control group(n=50)
Males Females Total % Males Females Total %
Hypertensives 15 17 32 64 4 4 8 16
Non-
hypertensives
12 6 18 36 18 24 42 84
In  the  study  group,  the  systolic  blood  pressure  ranged  from 110  to
160 mmHg with a mean value of 135.04 mmHg and a standard deviation
of 13.28 mmHg.
In the control group, the systolic blood pressure value varied from
70 to 100mmHg, with a mean value of 128.40 mmHg and a standard
deviation of 10.91 mmHg.
In the study group, the diastolic blood pressure ranged from 110 to
158 mmHg, with a mean value of 82.16 mmHg and a standard deviation of
8.30 mmHg.
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In the control group, the diastolic blood pressure ranged from 70 to
100 mmHg, with a mean value of 78.56 mmHg and a standard deviation of
8.26 mmHg.
LIPID PROFILE
SERUM TOTAL CHOLESTEROL
In the study group, the value of serum total cholesterol ranged
between 155 to 293 mg/dL with a mean value of 215.70 mg/dL and a
standard deviation of 31.00 mg/dL.
In the control group, the value ranged from 162 to 240 mg/dL with a
mean value of 185.12 mg/dL and a standard deviation of 23.45mg/dL.
TRIGLYCERIDES
In the study group, the value of triglycerides ranged from 130 to 270
mg/dL with a mean value of 184.42 mg/dL and a standard deviation of
31.86 mg/dL.
In the control group, the value ranged from 108 to 200 mg/dL with a
mean value of 148.00 mg/dL and a standard deviation of 21.42 mg/dL.
HIGH DENSITY LIPOPROTEIN (HDL)
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In the study group, HDL value ranged from 28 to 59 mg/dL with a
mean value of 38.54 mg/dL and a standard deviation of 9.02 mg/dL.
In the control group, HDL value ranged from 35 to 60mg/dL with a
mean value of 49.60 mg/dL and a standard deviation of 8.65 mg/dL.
LOW DENSITY LIPOPROTEIN (LDL)
In the study group, LDL values ranged from 75 to 210 mg/dL with a
mean value of 140.24 mg/dL and a standard deviation of 33.36 mg/dL.
In the control group, LDL values ranged from 73 to 168 mg/dL with
a mean value of 104.62 mg/dL and a standard deviation of 27.11 mg/dL.
BLOOD GLUCOSE
The study group had fasting blood glucose of 138.06 ± 17.13 mg/dL
and 2-hour postprandial blood glucose of 223.12 ± 30.63 mg/dL.
In the control group, the values were 85.34±6.75mg/dL and
112.64±26.76 mg/dL respectively.
GLYCEMIC CONTROL
Glycemic control was measured by using the level of HbA1C
(glycosylated haemoglobin) in blood. In the study group, HbA1C varied
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from 6.6 to 9.2 gm/dL with a mean and standard deviation of 7.97 and 0.85
gm/dL respectively.
In the control group, the value ranged from 4 to 5.5 gm/dl with a
mean of 4.94 and a standard deviation of 0.39gm/dL. Patients in the study
group were divided into two groups based on the level of HbA1C. 28
patients had HbA1c?8 gm/dL, implying poor glycemic control.
Table 5- Distribution of cases according to glycemic control
HbA1C(gm/dL) Control of bloodglucose Number Percentage
   <8 Good       22      44
   ?8 Poor       28      56
Table 6- Clinical and Biochemical Characteristics Of Study Subjects
STUDY GROUP
(n=50)
CONTROL
GROUP (n=50)
P value
Age 41.10 ± 4.00 40.04 ± 4.28 0.204
BMI 25.10 ± 1.67 24.18 ± 1.43 0.004
SBP 135.04 ± 13.28 128.40 ± 10.91 0.007
DBP 82.16 ± 8.30 78.56 ± 8.261 0.032
T CH 215.70 ± 31.00 185.12 ± 23.45 <0.001
TG 184.42  ± 31.86 148.00 ± 21.42 <0.001
HDL 38.54 ± 9.02 49.60 ± 8.65 <0.001
LDL 140.24 ± 33.36 104.62 ± 27.11 <0.001
FBS 138.06 ± 17.13 85.34 ± 6.75 <0.001
PPBS 223.12 ± 30.63 112.64 ± 26.76 <0.001
HbA1C 7.97 ± 0.85 4.94 ± 0.39 <0.001
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Both the study and control groups were comparable with respect to
age  (p 0.204). The study group had higher body mass index(p 0.004),
higher systolic blood pressure(p 0.007), higher diastolic blood pressure(p
0.032), higher serum total cholesterol (p<0.001), higher triglyceride
levels(p<0.001), higher LDL cholesterol(p<0.001), lower HDL cholesterol
(p<0.001), higher fasting blood glucose (p<0.001), higher 2 –hour
postprandial blood glucose (p<0.001) and higher HbA1C levels (p<0.001).
hsCRP
The mean hsCRP level in type 2 DM subjects was 3.41 mg/L and
standard deviation is 1.16 mg/L. In the control group, the value was
2.35mg/L and standard deviation is 0.65mg/L.
For 39 diabetic patients, hsCRP was > 3.0 mg/dL (high risk).
PLASMA FIBRINOGEN
In the study group, plasma fibrinogen ranged from 276 to 463
mg/dL, the mean and standard deviation being 387.84 mg/dL and
57.11mg/dL respectively.
In the control group, the fibrinogen level varied from 170 to 376
mg/dl with a mean and standard deviation of 300.06 mg/dL and 50.59
mg/dL respectively.
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In 43 diabetic patients, the plasma fibrinogen level was above the
upper limit of normal (>350 mg/dl).
Table-7 Comparative Analysis Of hsCRP Level In The Study And The
Control Groups:
N Mean SD Std. error ofmean ‘t’ value
Study group 50 3.41 1.16 0.16
5.571Control
group
50 2.35 0.65 0.09
The p value is < 0.001. There was a highly significant positive
correlation between diabetic state and the hsCRP level.
Table-8 Comparative Analysis Of Plasma Fibrinogen Level In The
Study And Control Groups
N Mean SD Std error of
mean
‘t’ value
Study group 50 387.84 57.11 8.08 8.135
Control
group
50 300.06 50.59 7.16
The p value is <0.001. There was a highly significant positive
correlation between diabetic state and the plasma fibrinogen level.
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Table-9 Correlation Analysis Between Age, Body Mass Index, Systolic
Blood Pressure, Diastolic Blood Pressure And hsCRP In The Study
Group
Variables N Pearson Correlation(‘r’) P value
Age 50 0.187 0.194
BMI 50 0.577 <0.001
Systolic BP 50 0.573 <0.001
Diastolic BP 50 0.598 <0.001
In the study group, a statistically significant positive correlation (p
value <0.001) was found between Body Mass Index, systolic blood
pressure, diastolic blood pressure and hsCRP. There was no significant
correlation between age of the subject and hsCRP level.
Table-10 Correlation Analysis Between Age, Body Mass Index,
Systolic Blood Pressure, Diastolic Blood Pressure And Hscrp In The
Control Group
Variables N Pearson Correlation(‘r’) P value
Age 50 0.518 <0.001
BMI 50 0.653 <0.001
Systolic BP 50 0.587 <0.001
Diastolic BP 50 0.529 <0.001
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In the control group, a statistically significant positive correlation (p
value <0.001) was found between Body Mass Index, systolic blood
pressure, diastolic blood pressure and hsCRP. There was also significant
correlation between age of the subject and hsCRP level.
Table 11- CORRELATION ANALYSIS BETWEEN LIPID PROFILE
AND hsCRP IN THE STUDY GROUP
Variables N Pearson correlation(‘r’) p value
Serum total cholesterol 50 0.671 <0.001
Triglyceride 50 0.631 <0.001
HDL 50 0.765 <0.001
LDL 50 0.708 <0.001
In the study group, a statistically significant positive correlation (p value
<0.001) was observed between serum total cholesterol, triglyceride, HDL,
LDL and hsCRP.
Table  12-  Correlation  Analysis  Between Lipid  Profile  And hsCRP In
the control group
Serum total cholesterol 50 0.777 <0.001
Triglyceride 50 0.764 <0.001
HDL 50 0.791 <0.001
LDL 50 0.748 <0.001
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A statistically significant positive correlation (p value <0.001) was
noted between serum total cholesterol, triglyceride, HDL, LDL and hsCRP
in the control group.
 Table-13 Correlation Analysis Between Fasting Blood Glucose, 2-
Hour  Postprandial  Blood  Glucose,  Hba1c  And  Hscrp  Level  In  The
Study Group
Variables N Pearson correlation(‘r’) p value
Fasting blood glucose 50 0.853 <0.001
Postprandial blood
glucose
50 0.807 <0.001
HbA1C 50 0.937 <0.001
In  the  study  group,  a  statistically  significant  correlation  with  a  p
value <0.001 was noted between fasting blood glucose, 2-hour
postprandial blood glucose and hsCRP level. Also a statistically significant
positive correlation (p value<0.001) was found between Glycosylated
hemoglobin (HbA1C) and hsCRP in the study group.
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Table-14 Correlation Analysis Between Fasting Blood Glucose, 2-Hour
Postprandial Blood Glucose, HbA1C and hsCRP Level In The Control
Group
Variables N Pearson correlation(‘r’) p value
Fasting blood glucose 50 0.223 0.119
Postprandial blood
glucose
50 0.003 0.981
HbA1C 50 0.073 0.612
There was no statistically significant correlation between fasting
blood glucose, 2-hour postprandial blood glucose and hsCRP in the control
group. And there was no statistically significant correlation between
HbA1C and hsCRP in the control group.
Table-15 Correlation Analysis Between Age, Body Mass Index,
Systolic Blood Pressure, Diastolic Blood Pressure And Plasma
Fibrinogen In The Study Group
Variables N Pearson Correlation(‘r’) P value
Age 50 0.215 0.134
BMI 50 0.553 <0.001
Systolic BP 50 0.568 <0.001
Diastolic BP 50 0.567 <0.001
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In the study group, a statistically significant positive correlation with
a p value of <0.001 was found between Body Mass Index, systolic blood
pressure, diastolic blood pressure and plasma fibrinogen. There was no
statistically significant correlation between age of the subject and plasma
fibrinogen.
Table-16 Correlation Analysis Between Age, Body Mass Index,
Systolic Blood Pressure, Diastolic Blood Pressure And Plasma
Fibrinogen In The Control Group
Variables N Pearson Correlation(‘r’) P value
Age 50 0.512 <0.001
BMI 50 0.583 <0.001
Systolic BP 50 0.523 <0.001
Diastolic BP 50 0.454 <0.001
In the control group, a statistically significant positive correlation was
observed between Body Mass Index, systolic blood pressure, diastolic
blood pressure, and plasma fibrinogen with p value of <0.001. Age also
significantly correlated.
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Table-17 Correlation Analysis Between Lipid Profile And Plasma
Fibrinogen In The Study Group
Variables N Pearson correlation(‘r’) p value
Serum total cholesterol 50 0.641 <0.001
Triglyceride 50 0.601 <0.001
HDL 50 0.705 <0.001
LDL 50 0.672 <0.001
In the study group, a statistically significant positive correlation with a p
value of <0.001 was found between serum total cholesterol, triglycerides,
HDL, LDL and plasma fibrinogen.
Table 18- Correlation Analysis Between Lipid Profile And Plasma
Fibrinogen In The Control Group
Variable N Pearson correlation(‘r’) p value
Serum total cholesterol 50 0.705 <0.001
Triglyceride 50 0.700 <0.001
HDL 50 0.699 <0.001
LDL 50 0.673 <0.001
In the control group, a statistically significant positive correlation was
observed between serum total cholesterol, triglycerides, HDL, LDL and
plasma fibrinogen with p value of<0.001.
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Table-19 Correlation Analysis Between Fasting Blood Glucose, 2-Hour
Postprandial Blood, Hba1c And Plasma Fibrinogen Level In The
Study Group
Variables N Pearson correlation(‘r’) p value
Fasting blood glucose 50 0.866 <0.001
Postprandial blood
glucose
50 0.815 <0.001
HbA1C 50 0.973 <0.001
In the study group, a statistically significant positive correlation with a p
value of <0.001 was found between fasting blood glucose, 2-hour
postprandial blood glucose and plasma fibrinogen. In the study group,
statistically significant positive correlation with a p value of <0.001 was
observed between Glycosylated haemoglobin (HbA1C) and plasma
fibrinogen.
Table-20 Correlation Analysis Between Fasting Blood Glucose, 2-Hour
Postprandial  Blood  Glucose  And  Plasma  Fibrinogen  Level  In  The
Control Group
Variable N Pearson correlation(‘r’) p value
Fasting blood glucose 50 0.231 0.107
Postprandial blood
glucose
50 0.015 0.919
HbA1C 50 0.150 0.300
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There was no statistically significant correlation fasting blood
glucose, 2-hour postprandial blood glucose and plasma fibrinogen in the
control group. There was no statistically significant correlation between
Glycosylated hemoglobin level and plasma fibrinogen level in the control
group.
Table-21 Correlation Analysis Between Hscrp And Plasma Fibrinogen
In The Study Group
Variable N Pearson correlation (‘r’) p value
hsCRP 50 0.971 <0.001
In the study group, statistically significant positive correlation with a p
value of <0.001 was found between hsCRP and plasma fibrinogen.
Table-22 Correlation Analysis Between Hscrp And Plasma Fibrinogen
In The Control Group
Variable N Pearson correlation (‘r’) p value
hs-CRP 50 0.981 <0.001
A statistically significant correlation (p value <0.001) was observed
between hsCRP and plasma fibrinogen in the control group.
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Table-23 Correlation Between Hscrp And Plasma Fibrinogen Level
With Glycemic Control In Diabetics
Variable
HbA1C<8
(n= 72 )
HbA1C?8
(n= 28 )
t value P value
Fibrinogen
(mean ± SD) 310.29±48.93
430.50±
24.80 12.370 <0.001
hs CRP
(mean ± SD) 2.36±0.39 4.20±0.78 11.90 <0.001
In the study group plasma fibrinogen level was higher in patients
with poor glycemic control (HbA1C ? 8 gm/L) (430.50 ± 24.80) than in
those with good glycemic control (HbA1C < 8gm/L) ( 310.29 ± 48.93)
with a significant p value <0.001.
In the study group hsCRP level was also higher in diabetics with
poor glycemic control (HbA1C ? 8 gm/L) (94.20 ± 0.78) than in those with
good glycemic control (HbA1C < 8gm/L) (2.36 ± 0.39). The p value was
significant (<0.001).
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Table-24 Clinical And Biochemical Characteristics In Normal And
Abnormal Hs-Crp Levels
PARAMETERS
Normal hs-CRP
(hs-CRP <3.0)
(N = 11)
Abnormal
hs-CRP
(hs-CRP >3.0)
(N = 39)
t p value
Age(years) 40.82 ± 2.86 41.18 ± 4.30 -0.262 0.794
BMI(kg/m2) 23.77 ± 1.58 25.47 ± 1.51 -3.272 0.002
Systolic BP(mmHg) 125.82 ± 12.02 137.64 ± 12.57 -2.781 0.008
Diastolic BP(mmHg) 76.18 ± 8.36 83.85 ± 7.56 -2.903 0.006
Total cholesterol
(mg/dL)
186.45 ± 34.66 233.95 ± 24.61 -4.065 <0.001
Triglycerides(mg/dL) 153.55 ± 27.39 193.13 ± 27.53 -4.216 <0.001
HDL(mg/dL) 48.91 ± 9.80 35.62 ± 6.30 -5.428 <0.001
LDL(mg/dL) 107.09 ± 38.09 149.59 ± 25.40 -4.366 <0.001
Fasting blood
glucose(mg/dL)
116.27 ± 12.38 144.21 ± 12.72 -6.468 <0.001
Postprandial blood
glucose(mg/dL)
185.91 ± 22.88 233.62 ± 23.63 -5.953 <0.001
HbA1C 6.80 ± 0.25 8.29  ± 0.65 -7.353 <0.001
When the study subjects were characterised as high risk using
hsCRP cut-off >3.0 mg/L, the subjects with abnormal hsCRP (3.0mg/L)
had higher BMI   (p 0.002), higher systolic blood pressure(p 0.008), higher
diastolic blood pressure (p 0.006), higher serum total cholesterol
(p<0.001), higher triglyceride levels (p<0.001), higher HDL cholesterol
(p<0.001), higher LDL cholesterol (p<0.001), higher fasting blood glucose
(p<0.001), higher 2-hour postprandial blood glucose (p<0.001) and higher
HbA1C levels (p<0.001).
Figure 1: Distribution of cases and controls by age
group
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Figure 2: Distribution of subjects in study group
according to Body Mass Index
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Figure3: Distribution of subjects in control group
according to Body Mass Index
0
37
13
0
0
5
10
15
20
25
30
35
40
<18.5 18.5 – 24.9 25 – 29.9 30 – 34.9
BMI(kg/m2)
Nu
m
be
r o
f I
nd
iv
id
ua
ls
Figure 4: Distribution of cases and controls
according to Body Mass Index
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Fiqure 5: Hypertension in the study group and control
group
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Figure 6- Distribution of cases according to glycemic
control
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DISCUSSION
Diabetes is now considered to be a proinflammatory and
procoagulant state. Diabetes and insulin resistance are associated with a
procoagulant milieu that may promote atherothrombosis by facilitating the
expansion of nascent thrombi generated by plaque disruption156. The
elevated levels of coagulation factors, persistently activated thrombogenic
pathways and impaired fibrinolysis in patients with diabetes predisposes
them to arterial thrombosis157,158. Fibrinogen level has emerged as an
important and independent predictor of cardiovascular disease and
coronary events in a number of prospective studies including the
Gothenburg, Northwick Park Heart Study153 and the Framingham Heart
Study149.
Diabetes is also a proinflammatory state and low grade chronic
inflammation (‘microinflammation’) is a key factor in the genesis and
rupture of atheromatous plaque127. Highly sensitive C-reactive protein, a
marker of inflammation, has also emerged as an important, independent
predictor of cardiovascular risk in various studies159,160.
In this study an attempt was made to compare the risk of coagulation
marker fibrinogen and the inflammatory marker, hsCRP in type 2 diabetics
and matched controls.
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The study and control population were comparable with respect to
age (41.10 ± 4.00 in study group vs 40.04 ± 4.28 in control group; p
0.204). Diabetic subjects have higher Body Mass Index (BMI) in this
study. This was further confirmed by the study done by Ni Mhurchu et al.
(2006)161. Cosin Aguilar et al. (2007) from his study state showed higher
prevalence of diabetes in the obese patients162. NHANES (2005) report and
Eric and John (2006) indicates that most adults with diagnosed diabetes
were overweight or obese, prevalence of overweight or obesity was 85.2 %
and the prevalence of obesity was 54.8% 163,164.
Systolic and diastolic blood pressure was higher in diabetic subjects.
David and Paul165 (2004) showed that the blood pressure and blood
pressure progression were strong and independent predictors of incident
type 2 diabetes among initially healthy women. The NHANES (1988-
1994) disclosed that 71% of diabetic individuals were found to have
hypertension (Geiss, et al. 2002)166.
The study group also had higher levels of serum total cholesterol,
triglycerides, LDL cholesterol and lower levels of HDL cholesterol.
Diabetic dyslipdemia (Erkelens)92 is well known in various studies
including the Heart Protection Study (HPS)94, Anglo-Scandinavian Cardiac
Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA)96, the Collaborative
Atorvastatin Diabetes Study (CARDS)97, the Lescol Intervention
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Prevention Study (LIPS)99,  and  the  Cholesterol  and  Recurrent  Events
(CARE) study.
In our study, the fasting blood glucose, 2-hour postprandial blood
glucose and Hb1Ac was higher in the diabetic subjects than normal
subjects. The present study showed a significant increase of hsCRP in
subjects with type 2 diabetes (3.4 ± 1.16 in diabetics vs 2.35 ± 0.65 in
controls). This  is  in  accordance  with  several  studies  including  a  study  by
Yuan G et al. in 2006 which showed that in comparison with normal
control (healthy people) serum hsCRP was significantly increased in
impaired glucose tolerance (IGT) and type-2 diabetes mellitus group
(P<0.001), although there was no significance between the two
groups167.The Pickup’s group(1997)113, the Tan’s group (2002)114, Ford
and Co-workers in the NHANES III(2003)115 ,all demonstrated a higher
level of hsCRP in diabetics than in those with normal fasting glucose. Also
Graham T.E et al. in 2006  showed that subjects with type 2 diabetes had
higher baseline levels of C-reactive protein, interleukin-6 and free fatty
acids than those with impaired glucose tolerance168. In a study in
Bangladesh in 2007 by Rosy N, showed that hsCRP was significantly
higher in Gestational diabetes mellitus (GDM) group (9.56 mg/L) than in
controls (normal pregnant group, 2.19 mg/L)169.
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There are only few studies of hs-CRP in Asian Indians, a very high-
risk group for diabetes. (Mohan et al. 2001; Mohan et al. 2003; Wild et al.
2004)170-172. There are studies by western authors which shows that Asian
Indians has higher levels of hsCRP. In a study by Chamber et al. in the
year 2001, the mean CRP concentration was observed to be 17% higher in
Indian Asian than with European White173.
In our study, hsCRP did not have statistically significant correlation
with age in the study group, where as it did show a significant positive
correlation in the control group. The elevation in hsCRP with increasing
age is well demonstrated in other studies by Rieko Hayaishi-Okano et al.
(2002)174, Safiullah Amanullah et al (2010)175, Rudrajit Paul et al (2011)176
and various other studies. This variation in our study can probably be
attributed to the small sample size.
In our study, serum hsCRP levels positively correlated with
anthropometric variables such as Body Mass Index (BMI), systolic and
diastolic blood pressure, serum total cholesterol, serum triglycerides, LDL
cholesterol and inversely with HDL cholesterol levels which is accordance
with  earlier  studies  (Francisco  et  al. 2005177;  Li  CZ  et  al.  2004178;
Taniguchi et al. 2002179; Earl and Wayene, 2004180; Wu et al.2006181, Festa
et al.2000120). Pick up et al. in 1997 showed positive correlation between
hyper triglyceridemia and diabetes mellitus and CRP levels113. Other
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studies have shown that CRP levels are significantly associated with
obesity (Visser et al. 2000182; Pradhan et al. 2001183).
The correlation of hsCRP with fasting plasma glucose and HbA1c
observed in our study in diabetics is similar to the previous studies (Li CZ,
et al. 2004178;  Pradhan  et  al.  2001183).  Aronson  et  al.  in  2004  in  a
population based study showed hsCRP to be independently associated with
fasting plasma glucose184. In our study serum hs CRP levels showed
positive correlation with glycemic control (HbA1C). The relationship of
hsCRP with glycemic control and its influence on inflammation was
shown in a prospective study by Rodriguez and Guerrero, in 1993 on type
2 diabetic subjects which suggested a decrease in hsCRP levels with a
decrease in HbA1C185.
In our study we characterized diabetics as high risk using an hsCRP
cut-off value >3.0 mgs /L .We found that the high risk subjects with
hsCRP>3.0 mgs/L had higher body mass index, systolic blood pressure,
diastolic blood pressure, serum total cholesterol, triglyceride, LDL
cholesterol, fasting plasma glucose, 2-hour postprandial plasma glucose
and HbA1c levels and lower HDL cholesterol than the subjects with
normal hs-CRP ( hs-CRP < 3.0 mgs/L). This was in accordance with
studies done by Safiullah Amanullah et al. in 2010175 and Festa et al in
2000120 .
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In our study, plasma fibrinogen levels is significantly elevated in
diabetics as compared to controls. This was in accordance with
observations of Ceriello A et al. (1994)186 and  Jain  A  et  al.  (1999)187,
Wilson PW et al. (2003)147 and Dunn EJ.et al.(2004)148.
A statistically significant positive correlation was noted in our study
between fibrinogen level  and body mass index, comparable to the
observation of Krobot et al. in his study189.In our study, we did not observe
significant positive correlation between plasma fibrinogen level and age in
the study group whereas age showed significant correlation with plasma
fibrinogen in the control group. Krobot et al. in his study showed the
positive correlation between age and plasma fibrinogen level189. This
variation in our study can probable be attributed to the small sample size.
Our study also showed a significant positive correlation between
plasma fibrinogen level and hypertension. This was in accordance with a
study by Folson et al .1998190. In our study, plasma fibrinogen levels also
correlated with serum total cholesterol. Similar results were shown by
Martin Halle et al.1996191. In our study plasma fibrinogen level also
correlated with higher levels of triglyceride, LDL cholesterol and lower
levels of HDL cholesterol. Similar results were observed in a meta analysis
of various prospective studies by The Fibrinogen Studies Collaboration in
the year 2007192.
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In  our  study,  a  positive  correlation  was  found  between  plasma
fibrinogen and HbA1C level in diabetics. Higher levels of fibrinogen was
observed in those with poorer glycemic control. This was in accordance
with results from a study by Elkhawnd et al156. Kannel B et al, in his study
showed that there was an increase in fibrinogen values throughout the
range of blood sugar levels in diabetics149. Graziella Bruno et al. studied
the association of serum fibrinogen level with glycemic control in 1525
patients and found that noninsulin dependent diabetic patients had a high
prevalence of hyperfibrinogenemia and that fibrinogen level was
independently associated with HbA1c value150. In another study, Patnaik B
et al. in 1998, had observed that hyperfibrinogenemia can be controlled
with adequate control of blood sugar37.
In our study we found a significant positive correlation between
hsCRP and plasma fibrinogen levels in both diabetics and controls.
Rudrajit Paul et al.2011176, Takebayashi Kohzo et al 2006193, The
Fibrinogen studies Collaboration 2007192 and various other studies also
showed significant positive correlation between hs CRP and fibrinogen
levels.
However, there is a need to validate the data on larger sample size
and in diabetic subjects with cardiovascular disease.
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LIMITATIONS OF THE STUDY
1. We would like to acknowledge that a relatively small number of
patients were evaluated and that the number of subjects required to
detect a significant difference in the predictive power of the hsCRP
and plasma fibrinogen has not been prospectively determined.
2. The study is a hospital based study and may not be representative of
the general population.
3.  In this study hsCRP and plasma fibrinogen levels were estimated only
once. Ideally serial measurements should have been done, as both are
acute phase reactants.
4. Confounding effects of obesity, hypertension and dyslipdemia have
not been taken into account.
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CONCLUSIONS AND SUMMARY
? The elevated levels of highly sensitive C-reactive protein (hs CRP)
points to the existence of a proinflammatory state in diabetes
mellitus.
? The role of inflammation is more pronounced in patients with
uncontrolled diabetes when compared to those with glycemic
control.
? The elevated levels of plasma fibrinogen points to the existence of a
procoagulant state in diabetics.
? Hemostatic alterations are more pronounced in uncontrolled
diabetics when compared to better controlled diabetics.
? Body mass index, systolic blood pressure, diastolic blood pressure,
levels of serum total cholesterol, triglycerides, LDL cholesterol and
HDL cholesterol correlate independently with both hsCRP and
plasma fibrinogen levels.
? The levels of hsCRP and plasma fibrinogen correlated with each
other.
? Both elevated hsCRP levels and hyperfibrinogenemia may precede
clinically demonstrable vascular complications.
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? Hence, assessment of hsCRP and plasma fibrinogen levels may help
in the evaluation and management of diabetes mellitus, especially to
identify individuals with high cardiovascular risk among those
without clinically demonstrable vascular complications. This helps
to educate them regarding lifestyle modifications and
pharmacotherapy of traditional risk factors and the need for good
glycemic  control  with  a  greater  emphasis,  in  order  to  prevent
cardiovascular complications in the future. Also regular follow up of
these high risk patients can lead to early detection of cardiovascular
events in the future , thereby reducing economic burden and
improving the quality of life.
PROFORMA
A COMPARATIVE ANALYSIS OF HIGH-SENSITIVITY
C-REACTIVE
PROTEIN (hs-CRP) AND FIBRINOGEN LEVELS IN TYPE 2
DIABETICS AND MATCHED CONTROLS.
DEPARTMENT OF MEDICINE
STANLEY MEDICAL COLLEGE & HOSPITAL
Name :                                        Age: Gender :
Occupation :                               IP No / OP No :
Address / Contact No. DOA:
DOD:
CHIEF COMPLAINTS :
Polyuria :   +/- Polydypsia +/
Polyphagia :   +/- Nocturia +/
Weight loss :   +/- Tingling Numbness +/
Vision :   +/- Burning Micturition +/
Swelling of the feet :   +/- Puffiness of face +/
Skin lesion :   +/- Dyspnoea +/
Claudication :   +/- TIA     - +/
Chest Pain (Anginal) :   +/- Any Other
Age at diagnosis : Duration
Prior admissions to hospital for the same:
Treatment : Diet + OHA
Insulin
Control : Good/Fair/Uncontrolled
Other illness (if any) & medications :
Family History of :
DM HTN :
HD Any Other :
Personal History
EXAMINATION :
Build : Height :
Weight : BMI :
Puffiness of face :   +/- WC :
Pulse Rate :
PERIPHERAL PULSES :
RIGHT       LEFT
Carotid : +/- : +/-
Temporal artery : +/- : +/-
Brachial : +/- : +/-
Radial : +/- : +/-
Femoral : +/- : +/-
Popliteal : +/- : +/-
Post. Tibial : +/- : +/-
Dorsalis pedis : +/- : +/-
SKIN CHANGES :
Shiny Skin :
Loss of Hair :
Ulcers :
Gangrene
Blood pressure : Supine :
3 Min. standing
ABPI :
Optic fundus
CENTRAL NERVOUS SYSTEM
Other Cranial Nerves :
Peripheral Neuropathy - Ankle Jerk :
 Pinprick Sensation :
Vibration Sense :
CARDIOVASCULAR SYSTEM
Heart Sounds :  Evidence of Cardiac failure : +/-
RESPIRATORY SYSTEM
PER ABDOMEN
INVESTIGATIONS
CBC -     Hb    :
TC :
DC   :
ESR  :
Platelet Count:
BT
CT
RFT -     Urea
- Creatinine
Serum Electrolytes       -     Sodium
- Potassium
- Chloride
- Bicarbonate
FBS
PPBS
HbA1C
Plasma fibrinogen
hs-CRP
Fasting lipid profile      - Total Cholesterol
 -Triglycerides
 - HDL
.    - LDL
 -VLDL
LFT URINE -  Albumin
-  Sugar
-  Microscopy
-  Ketones
TFT
ECG
Chest X – ray ECHO
MASTER CHART   - STUDY GROUP
NAME AGE SEX Ht(cm) Wt(kg) BMI SBP DBP T CH TG HDL LDL FBS PPBS HbA1c fibrin hsCRP
1 SELVAKUMAR 32 M 160 63 24.6 124 76 205 170 37 134 136 226 7.3 355 3.1
2 NATARAJAN 34 M 170 71 24.56 126 76 220 197 39 141 134 240 8.1 405 3.6
3 ANTONY 38 M 162 62 23.62 118 70 199 149 49 120 159 281 8.2 410 3.7
4 PUSHPARAJ 36 M 162 63 24 122 74 166 130 57 83 124 198 6.6 280 1
5 PRAMOD 36 M 165 66 24.24 120 76 210 167 37 139 120 198 7.3 352 3.1
6 PRABHAKARAN 39 M 167 60 21.51 124 72 155 133 53 75 114 176 6.6 281 1
7 SELVARAJ 38 M 167 68 24.38 132 82 196 189 36 122 138 230 8.4 421 3.9
8 RAHMAN 37 M 157 60 24.34 140 86 230 190 36 156 150 240 8.6 431 4.2
9 ANKAAIAH 36 M 158 59 23.63 110 70 188 155 59 91 129 198 8.1 390 3.6
10 PANEERSELVAM 39 M 152 56 24.24 122 76 203 163 39 131 125 180 7.3 357 3.1
11 VENKETESH 39 M 161 63 24.3 134 86 201 185 35 129 152 230 8.4 375 3.9
12 MANIKANDAN 44 M 157 61 24.75 136 90 209 177 36 137 148 250 8.2 371 3.7
13 MANIMARAN 43 M 158 61 24.43 136 82 211 189 35 138 132 244 8.7 437 4.3
14 NOOR AHMED 40 M 160 61 23.82 138 84 207 185 35 135 152 249 8.6 433 4.2
15 SELVARAJ 42 M 160 63 22.58 118 74 170 136 56 88 117 180 6.7 290 1.1
16 DEVA JOE 41 M 165 65 23.88 126 74 180 150 56 94 133 231 7.3 352 3.1
17 MEGHANATHAN 44 M 155 53 22.06 114 70 170 134 55 88 106 166 6.6 283 1
NAME AGE SEX Ht(cm) Wt(kg) BMI SBP DBP T CH TG HDL LDL FBS PPBS HbA1c fibrin hsCRP
18 MURUGANADHAN 44 M 154 58 24.45 144 82 224 176 37 152 156 197 8.3 416 3.8
19 KUMARAN 43 M 156 56 23.01 120 70 168 146 52 88 102 158 6.7 290 1.2
20 THANKARAJ 42 M 162 65 24.77 140 84 240 180 35 169 147 205 8.5 428 4
21 VIJAYARAGHAVAN 42 M 172 73 24.68 150 80 220 188 35 147 136 254 8.8 444 4.4
22 BEER MOHAMMED 41 M 160 65 25.39 136 92 280 260 30 198 158 260 9 455 4.6
23 KARTHIK 44 M 157 63 25.56 148 86 243 270 34 155 133 206 7.7 371 3.3
24 PANCHALINGAM 40 M 162 70 26.67 144 92 254 189 31 185 145 241 8.3 417 3.8
25 PAUL RAJ 43 M 167 75 26.89 138 90 252 199 30 182 131 223 7.7 373 3.3
26 ANTONY RAJ 48 M 165 70 25.71 160 86 222 189 32 152 155 250 9.1 457 4.7
27 PANCHATJARAM 47 M 163 68 25.59 146 86 214 192 28 147 162 261 8.9 448 4.5
28 PUSHPA 32 F 155 65 27.05 124 72 232 180 32 170 149 249 9.2 463 4.8
29 LATHA 36 F 152 55 23.81 112 70 164 146 54 81 98 170 6.6 276 1
30 AZEERA BEGAM 36 F 157 60 24.34 110 70 212 182 40 135 122 180 7.1 353 3.1
31 GUNASUNDARI 39 F 160 68 26.56 132 90 242 210 30 170 128 241 7.5 360 3.2
32 AMINA 38 F 158 63 25.24 150 90 249 200 30 183 134 228 7.5 363 3.2
33 LOGANAYAKI 38 F 165 70 25.71 142 88 237 191 34 165 161 251 9.2 461 4.8
34 RIYANA 40 F 162 65 24.78 134 86 204 160 36 136 120 194 7.1 352 3
35 VANAJA 41 F 162 63 24 124 72 186 150 59 97 129 214 6.9 315 1.3
36 AMBIKA 41 F 153 54 23.07 122 72 166 142 49 89 107 167 6.7 291 1.1
NAME AGE SEX Ht(cm) Wt(kg) BMI SBP DBP T CH TG HDL LDL FBS PPBS HbA1c fibrin hsCRP
37 MAHALAKSHMI 43 F 166 71 25.77 144 82 242 202 36 166 139 234 7.2 361 3
38 SUGUNA 43 F 167 73 26.18 134 90 212 190 34 140 145 251 8.8 442 4.4
39 MANJULA 43 F 155 68 28.3 156 94 250 245 32 169 141 231 8.5 427 4
40 FATHIMA 44 F 158 67 26.84 150 96 260 210 31 187 123 188 7.2 361 3
41 SHANMUGAVALLI 44 F 158 68 27.24 136 84 259 214 33 183 150 257 9 452 4.6
42 MALLIKA 42 F 156 62 25.48 148 92 205 180 34 135 160 242 9.1 457 4.7
43 KALAVATHI 42 F 166 73 26.49 150 88 200 189 30 132 157 231 8.3 413 3.8
44 TAMILSELVI 41 F 160 65 25.39 142 90 220 170 35 151 155 229 8.7 438 4.3
45 YAMUNA 45 F 155 75 30.82 150 100 293 242 34 210 163 252 8.8 443 4.4
46 MALAR 45 F 162 65 24.77 126 76 200 220 35 121 149 246 8.5 423 4
47 BHANU 45 F 158 68 27.24 144 84 212 195 35 138 132 212 7.1 357 3.1
48 MEENAKSHI 48 F 158 60 24.03 144 80 223 179 32 155 142 241 8.6 434 4.2
49 VIJAYALAKSHMI 48 F 157 69 27.99 152 96 251 240 33 169 169 270 9.2 463 4.8
50 KALAICHELVI 49 F 152 60 25.97 160 80 229 196 35 154 136 206 7.5 365 3.3
MASTER CHART   - CONTROL GROUP
NAME AGE SEX Ht Wt BMI SBP DBP T CH TG HDL LDL FBS PPBS HbA1c fib hsCRP
1 GABRIEL 31 M 162 63 24 120 80 162 130 46 90 82 94 4.1 170 1.1
2 YESUDOSS 35 M 160 60 23.44 130 80 173 128 56 91 78 104 4 182 1
3 PANDIDUARI 35 M 167 65 23.3 132 82 185 142 60 97 73 114 4 194 1.3
4 GANAPATHY 36 M 155 53 22.06 110 70 170 136 56 87 78 110 4.2 250 1.6
5 SARAVANAN 37 M 162 61 23.24 118 70 174 142 58 88 98 120 5.1 210 1.4
6 BABURAJ 38 M 167 65 23.3 120 70 168 108 57 89 80 135 5.3 224 1.5
7 VELLIGOWNDER 38 M 158 62 24.83 130 80 174 130 60 88 93 130 5.4 248 1.6
8 ARUN KUMAR 38 M 170 71 24.57 130 78 180 149 55 95 95 138 5.4 260 1.7
9 SRIDHAR 38 M 174 77 25.43 134 82 220 170 38 148 82 131 4.3 356 3.1
10 RAJKUMAR 39 M 165 70 25.71 130 84 207 189 37 132 81 113 5 351 3.1
11 ELANGO 40 M 162 64 24.39 120 72 170 134 55 88 76 115 5.5 244 1.6
12 RAJA 41 M 166 63 22.86 130 74 163 130 52 85 86 125 5.2 298 2.3
13 BALARAMAN 41 M 155 52 21.64 124 74 170 140 52 90 95 122 5.4 320 2.5
14 MUTHU 42 M 175 68 22.2 126 74 173 138 58 87 85 115 5.1 310 2.4
15 JAADEESHAN 43 M 172 72 24.33 128 80 154 126 47 82 74 110 5.3 320 2.5
16 ARUL RAJ 43 M 169 66 23.1 130 82 176 122 56 96 77 118 5.1 301 2.3
17 ANANDAN 43 M 157 54 21.9 128 80 173 118 52 97 75 98 5.3 267 1.8
18 MANOHARAN 43 M 155 56 23.3 128 80 170 130 59 85 77 102 5 289 2.1
19 SYED BASHA 44 M 171 72 24.62 142 90 214 160 39 143 92 108 5 352 3.1
20 BALAMURUGAN 44 M 170 68 23.53 144 92 175 143 57 89 94 124 4.2 300 2.3
21 AHMED 44 M 158 66 26.44 150 100 240 192 37 164 90 130 5.4 376 3.4
22 CHINNADURAI 48 M 161 67 25.85 148 100 233 177 35 162 85 126 4.6 365 3.3
23 ANBUMALAR 30 F 154 56 23.61 120 70 174 139 59 87 94 114 4.8 310 2.4
24 SINDHU 33 F 158 58 23.23 114 72 166 142 54 84 80 132 5 259 1.7
25 DIVYARANI 33 F 154 60 25.23 112 70 202 159 41 129 82 110 4.8 351 3.1
26 INDUMATHI 35 F 162 65 24.78 116 70 175 134 57 91 75 118 5.2 260 1.7
27 ALANGARAM 35 F 155 52 21.64 118 72 174 118 53 97 78 112 4.9 298 2.3
28 REVATHY 36 F 152 50 21.64 120 74 180 152 58 92 82 100 5.1 271 1.8
29 ABHINAYA 36 F 159 61 24.13 124 76 168 146 52 87 85 120 5 269 1.8
30 SANEETHA 36 F 161 64 24.69 120 70 173 138 54 91 90 125 5.2 310 2.4
31 UMA 37 F 160 69 26.95 134 80 222 175 36 151 93 130 5.4 361 3.2
32 NALINI 39 F 157 63 25.56 130 80 208 171 39 134 94 132 4.9 352 3.1
33 THILAGAVATHY 40 F 155 58 24.14 120 70 168 145 55 84 81 14 4.8 301 2.3
34 SUNDARI 40 F 157 58 23.53 124 72 174 135 52 95 85 130 4.7 299 2.3
35 GEETHA 40 F 165 65 23.88 126 70 172 149 55 87 87 16 4.6 313 2.4
36 SITALAKSHMI 41 F 158 59 23.63 120 72 186 138 59 99 92 114 4.8 325 2.5
37 AROKYA MARY 41 F 158 61 24.44 124 74 177 145 58 90 94 117 4.9 315 2.4
38 CHITHRA 41 F 163 61 22.96 120 70 168 132 48 94 88 105 5 298 2.3
39 ANCY MARY 41 F 152 55 23.8 122 70 170 144 51 90 90 110 5.1 301 2.4
40 GEETHALAKSHMI 41 F 150 55 24.44 120 72 164 146 54 81 85 108 5.4 297 2.3
41 SINDHURI 42 F 150 53 23.56 124 76 166 142 49 89 91 130 5.3 280 2.2
42 INDRANI 42 F 151 55 24.12 124 78 177 135 58 92 90 126 5.2 303 2.3
43 AROKIAAMMAL 43 F 152 60 25.97 144 90 218 181 34 148 86 124 5.2 356 3.1
44 KANAKAMMAL 44 F 155 65 27.06 154 96 229 194 36 154 84 135 4.9 363 3.3
45 AMINA BEGAM 44 F 167 75 26.89 134 84 241 177 37 168 88 19 4.6 374 3.4
46 VANAJAMMAL 44 F 153 63 26.91 152 94 202 200 34 73 76 110 4.7 351 3.1
47 CHINTHAMANI 44 F 164 68 25.28 134 82 223 173 38 150 79 128 4.9 363 3.3
48 ELAKKIAMMAL 47 F 157 59 23.94 130 80 172 148 54 88 93 114 5 278 2.2
49 BHANUMATI 48 F 158 58 23.23 130 80 164 138 46 90 89 132 5.2 298 2.4
50 SHANAZ BEGAM 48 F 156 63 25.89 158 90 219 170 37 143 90 125 4.3 360 3.2

ABBREVIATIONS
hsCRP -  highly sensitive C-Reactive Protein.
Ht -  Height
Wt -  Weight
BMI -  Body Mass Index
SBP -  Systolic Blood Pressure
DBP -  Diastolic Blood Pressure
TCH - Total cholesterol
TG -  Triglyceride
HDL - High Density Lipoprotein
LDL -  Low Density Lipoprotein
FBS - Fasting blood Glucose
PPBS -  2-hour postprandial blood glucose
HbA1C -  Hemoglobin A1C
ADA - American Diabetes Association
AHA - American Heart Association
WHO - World Health Organization
IDF - International Diabetes Federation
